Sarina Tangyingyong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarina Tangyingyong has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Hala Abu-Fares
Department of Immunology, Mayo Clinic, Jacksonville, FL 32224, USA
1 shared publication - Thiti Susiriwatananont
Chulalongkorn University 1 Division of Medical Oncology, Department of Medicine, Faculty of Medicine , Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (9) , 2046
Dietary Fructose and Early-Onset Colorectal Cancer: Metabolic, Microbial, and Translational Perspectives
Early-onset colorectal cancer (eoCRC) is increasing globally, raising interest in modifiable dietary exposures that may contribute to its development. High fructose intake, particularly from sugar-sweetened beverages and high-fructose corn syrup, has been associated with colorectal neoplasia and eoCRC in epidemiologic studies. Experimental evidence suggests that fructose may promote colorectal tumorigenesis through enhanced uptake and metabolism, polyol pathway activation, glycolytic and lipogenic reprogramming, hypoxic adaptation, and interactions with the tumor microenvironment. Excess fructose reaching the colon may also impair intestinal barrier integrity and alter gut microbial composition and metabolite production. Preclinical models support a direct tumor-promoting effect of fructose independent of obesity, whereas human mechanistic and microbiome data remain limited. This review summarizes current evidence linking fructose exposure with eoCRC and discusses emerging metabolic, microbial, and translational implications, while highlighting key gaps that must be addressed to establish causality and clinical relevance.
- 14 September 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (9) , 2046
Open AccessDietary Fructose and Early-Onset Colorectal Cancer: Metabolic, Microbial, and Translational Perspectives
Early-onset colorectal cancer (eoCRC) is increasing globally, raising interest in modifiable dietary exposures that may contribute to its development. High fructose intake, particularly from sugar-sweetened beverages and high-fructose corn syrup, has been associated with colorectal neoplasia and eoCRC in epidemiologic studies. Experimental evidence suggests that fructose may promote colorectal tumorigenesis through enhanced uptake and metabolism, polyol pathway activation, glycolytic and lipogenic reprogramming, hypoxic adaptation, and interactions with the tumor microenvironment. Excess fructose reaching the colon may also impair intestinal barrier integrity and alter gut microbial composition and metabolite production. Preclinical models support a direct tumor-promoting effect of fructose independent of obesity, whereas human mechanistic and microbiome data remain limited. This review summarizes current evidence linking fructose exposure with eoCRC and discusses emerging metabolic, microbial, and translational implications, while highlighting key gaps that must be addressed to establish causality and clinical relevance.